Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
VANCOUVER, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or […]